Conduit Pharmaceuticals Inc. (CDT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Conduit Pharmaceuticals Inc. (CDT) has a cash flow conversion efficiency ratio of -0.015x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.67 Million) by net assets ($1.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Conduit Pharmaceuticals Inc. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Conduit Pharmaceuticals Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Conduit Pharmaceuticals Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Conduit Pharmaceuticals Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Conduit Pharmaceuticals Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DSJ Keep Learning Limited
NSE:KEEPLEARN
|
0.014x |
|
Inomin Mines Inc
V:MINE
|
-0.133x |
|
Krida Jaringan Nusantara Tbk PT
JK:KJEN
|
0.001x |
|
Delixy Holdings Limited Ordinary Shares
NASDAQ:DLXY
|
N/A |
|
HITIQ Ltd
AU:HIQ
|
0.464x |
|
Marula Mining PLC
F:48U0
|
N/A |
|
Mynaric AG
XETRA:M0YN
|
0.271x |
|
Summit Minerals Ltd
AU:SUM
|
-0.048x |
Annual Cash Flow Conversion Efficiency for Conduit Pharmaceuticals Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Conduit Pharmaceuticals Inc. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see CDT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.26 Billion | $-15.55 Million | -0.012x | -100.86% |
| 2024-12-31 | $-6.79 Million | $-9.68 Million | 1.425x | -91.57% |
| 2023-12-31 | $-457.00K | $-7.72 Million | 16.904x | +7426.11% |
| 2022-12-31 | $-10.09 Million | $-2.27 Million | 0.225x | +100.22% |
| 2021-12-31 | $20.62K | $-2.15 Million | -104.321x | -- |
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the tre… Read more